Viridian Therapeutics Inc (1S1)

Currency in EUR
14.695
-0.280(-1.87%)
Delayed Data·
1S1 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
1S1 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
14.69514.695
52 wk Range
9.60423.400
Key Statistics
Bid/Ask
14.455 / 14.835
Prev. Close
14.975
Open
14.695
Day's Range
14.695-14.695
52 wk Range
9.604-23.4
Volume
-
Average Volume (3m)
946
1-Year Change
6.96%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
1S1 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Viridian Therapeutics Inc Company Profile

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company’s product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Compare 1S1 to Peers and Sector

Metrics to compare
1S1
Peers
Sector
Relationship
P/E Ratio
−5.8x−4.8x−0.5x
PEG Ratio
0.42−0.020.00
Price/Book
3.4x2.5x2.6x
Price / LTM Sales
4,647.0x28.7x3.2x
Upside (Analyst Target)
-161.9%40.5%
Fair Value Upside
Unlock14.4%4.4%Unlock

Earnings

Latest Release
Mar 03, 2025
EPS / Forecast
-1.30 / --
Revenue / Forecast
158.00K / --
EPS Revisions
Last 90 days

1S1 Income Statement

People Also Watch

21.60
VERA
-1.28%
5.995
FOLD
-4.54%
18.832
QBTS
-4.70%
17.10
IMVT
-6.66%
24.95
JANX
-3.93%

FAQ

What Stock Exchange Does Viridian Therapeutics Inc Trade On?

Viridian Therapeutics Inc is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Viridian Therapeutics Inc?

The stock symbol for Viridian Therapeutics Inc is "1S1."

What Is the Viridian Therapeutics Inc Market Cap?

As of today, Viridian Therapeutics Inc market cap is 1.19B.

What Is Viridian Therapeutics Inc's Earnings Per Share (TTM)?

The Viridian Therapeutics Inc EPS (TTM) is -3.33.

From a Technical Analysis Perspective, Is 1S1 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Viridian Therapeutics Inc Stock Split?

Viridian Therapeutics Inc has split 2 times.

How Many Employees Does Viridian Therapeutics Inc Have?

Viridian Therapeutics Inc has 143 employees.

What is the current trading status of Viridian Therapeutics Inc (1S1)?

As of 25 Jul 2025, Viridian Therapeutics Inc (1S1) is trading at a price of 14.70, with a previous close of 14.98. The stock has fluctuated within a day range of 14.70 to 14.70, while its 52-week range spans from 9.60 to 23.40.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.